Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab

Nadia Peragine; Maria Stefania De Propris; Stefania Intoppa; Maria Laura Milani; Paola Mariglia; Francesca Romana Mauro; Sara Raponi; Stefano Soddu; Antonio Cuneo; Gian Matteo Rigolin; Ilaria Del Giudice; Robin Foà; Anna Guarini

doi:10.3324/haematol.2020.262071

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab

Haematologica. 2020 Oct 5;106(5):1500-1503. doi: 10.3324/haematol.2020.262071.

Affiliations

¹ Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
² Italian Group for Adult Hematologic Diseases (GIMEMA) Foundation, Rome.
³ Hematology, Department of Medical Sciences, University of Ferrara, Ferrara.
⁴ Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome . rfoa@bce.uniroma1.it.
⁵ Department of Molecular Medicine, "Sapienza" University, Rome, Italy.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Piperidines
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Rituximab / therapeutic use
Treatment Outcome

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Rituximab
Adenine

Grants and funding

Funding: this work was supported by funds from Associazione Italiana Ricerca sul Cancro (AIRC), Special 5x1000 Program Metastases (21198), Milan (Italy) to RF. SI and MLM were supported by ROMAIL ONLUS, PM was supported by GIMEMA ONLUS.